USANA Health Sciences (NYSE:USNA) anticipates Q2 sales in the range between $253M – $256M, compared to $301M last year, and EPS of ~$0.91 – $0.95, compared with $1.36 in the prior-year period.
The company lowered its FY19 outlook, amid challenging consumer environment in China due to negative media coverage of the health products and direct selling industries
Forecasts sales of ~$1.02B – $1.06B as compared to prior guidance of $1.21B-$1.26B, with EPS of $3.70 – $4.10 down from prior guidance of $5-5.35
Q2 results will be released on July 23, 2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.